Oncology Pipeline

Research & Development

Our Pipeline

At Servier Pharmaceuticals, we are committed to building a robust portfolio of treatments starting with oncology and potentially expanding to other therapeutic areas. Advancing innovation for patients is at the heart of everything we do. Globally, we are continuously reinvesting 25 percent of our revenue (excluding generics) in our own research or through alliances and partnerships that drive research and development to address unmet patient needs in various therapeutic areas.

Our global pipeline includes more than a dozen oncology projects at varying stages of clinical development.

Hematological Malignancies

Molecule Area	Primary Indication	Partner	Territory	Phase

ONCASPAR^® (pegaspargase)	ALL		World	Registered
PRIMARY INDICATION Acute Lymphoblastic Leukemia		PARTNER		PARTNER World
PRIMARY INDICATION Acute Lymphoblastic Leukemia PARTNER TERRITORY World
	Acute Lymphoblastic Leukemia		World
ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase. Additional Information
ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase. Additional Information

ASPARLAS^™ (calaspargase pegol-mknl)	ALL		World	Registered
PRIMARY INDICATION Acute Lymphoblastic Leukemia		PARTNER		PARTNER World
PRIMARY INDICATION Acute Lymphoblastic Leukemia PARTNER TERRITORY World
	Acute Lymphoblastic Leukemia		World
ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years. Additional Information
ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years. Additional Information

PIXURVI^® (pixantrone)	NHL		World	Registered
PRIMARY INDICATION Non-Hodgkin’s Lymphoma		PARTNER		PARTNER World
PRIMARY INDICATION Non-Hodgkin’s Lymphoma PARTNER TERRITORY World
	Non-Hodgkin’s Lymphoma		World
PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.
PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

Anti-TIM-3	Lymphoma	Symphogen...	World	Phase 1
PRIMARY INDICATION Lymphoma		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.		PARTNER World
PRIMARY INDICATION Lymphoma PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. TERRITORY World
	Lymphoma	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.	World

MCL1 Inhibitor	AML	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Acute Myeloid Leukemia*		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Acute Myeloid Leukemia* PARTNER Novartis TERRITORY World except for North America and Japan
	Acute Myeloid Leukemia*	Novartis	World except for North America and Japan
*In combination with BCL-2 Inhibitor
*In combination with BCL-2 Inhibitor

BCL-2 Inhibitor	R/R AML + NHL + MM	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma	Novartis	World except for North America and Japan

BCL- 2 Inhibitor	R/R AML	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Acute Myeloid Leukemia	Novartis	World except for North America and Japan

BCL-2 Inhibitor	R/R NHL	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Non-Hodgkin’s Lymphoma	Novartis	World except for North America and Japan

BCL-2 Inhibitor	R/R MM	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Multiple Myeloma		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Multiple Myeloma PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Multiple Myeloma	Novartis	World except for North America and Japan

BCL-2 Inhibitor	R/R CLL	Novartis	Phase 1
PRIMARY INDICATION R/R Chronic Lymphocytic Leukemia		PARTNER Novartis	PARTNER
PRIMARY INDICATION R/R Chronic Lymphocytic Leukemia PARTNER Novartis TERRITORY
	R/R Chronic Lymphocytic Leukemia	Novartis

Anti-CD19	R/R ALL Pediatric	Allogene Therapeutics	World except for the United States	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric*		PARTNER Allogene Therapeutics		PARTNER World except for the United States
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric* PARTNER Allogene Therapeutics TERRITORY World except for the United States
	Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric*	Allogene Therapeutics	World except for the United States
*Based on Cellectis TALEN® genome editing platform
*Based on Cellectis TALEN® genome editing platform

Anti-CD19	R/R ALL Adult	Allogene Therapeutics	World except for the United States	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Adult*		PARTNER Allogene Therapeutics		PARTNER World except for the United States
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Adult* PARTNER Allogene Therapeutics TERRITORY World except for the United States
	Relapsed/Refractory Acute Lymphoblastic Leukemia Adult*	Allogene Therapeutics	World except for the United States
*Based on Cellectis TALEN® genome editing platform
*Based on Cellectis TALEN® genome editing platform

Anti-CD19	R/R NHL	Allogene Therapeutics	World except for the United States	Phase 1
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma*		PARTNER Allogene Therapeutics		PARTNER World except for the United States
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma* PARTNER Allogene Therapeutics TERRITORY World except for the United States
	Relapsed/Refractory Non-Hodgkin’s Lymphoma*	Allogene Therapeutics	World except for the United States
*Based on Cellectis TALEN® genome editing platform
*Based on Cellectis TALEN® genome editing platform

Anti-CD19	R/R ALL + NHL	Precision BioSciences	World except for the United States	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia + Non-Hodgkin’s Lymphoma*		PARTNER Precision BioSciences**		PARTNER World except for the United States
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia + Non-Hodgkin’s Lymphoma* PARTNER Precision BioSciences** TERRITORY World except for the United States
	Relapsed/Refractory Acute Lymphoblastic Leukemia + Non-Hodgkin’s Lymphoma*	Precision BioSciences**	World except for the United States
Based on ARCUS® genome editing platform *License option not yet exercised for Precision BioSciences CAR-T
Based on ARCUS® genome editing platform *License option not yet exercised for Precision BioSciences CAR-T

Anti-PD-1	Lymphoma	Symphogen...	World except for the United States	Phase 1
PRIMARY INDICATION Lymphoma		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.		PARTNER World except for the United States
PRIMARY INDICATION Lymphoma PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. TERRITORY World except for the United States
	Lymphoma	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.	World except for the United States

Anti-LAG-3	Lymphoma	Symphogen...	World	Phase 1
PRIMARY INDICATION Lymphoma		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.		PARTNER World
PRIMARY INDICATION Lymphoma PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. TERRITORY World
	Lymphoma	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.	World

Solid Tumors

Molecule Area	Primary Indication	Partner	Territory	Phase

Lonsurf^® (trifluridine/tipiracil)	mCRC Third Line	Taiho Pharmaceutical Co.	World except for the United States	Registered
PRIMARY INDICATION Third line metastatic Colorectal Cancer		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for the United States
PRIMARY INDICATION Third line metastatic Colorectal Cancer PARTNER Taiho Pharmaceutical Co. TERRITORY World except for the United States
	Third line metastatic Colorectal Cancer	Taiho Pharmaceutical Co.	World except for the United States
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Additional Information
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Additional Information

Lonsurf^® (trifluridine/tipiracil)	mCRC Second Line	Taiho Pharmaceutical Co.	World except for North America and Asia	Phase 1
PRIMARY INDICATION Second line metastatic Colorectal Cancer*		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for North America and Asia
PRIMARY INDICATION Second line metastatic Colorectal Cancer* PARTNER Taiho Pharmaceutical Co. TERRITORY World except for North America and Asia
	Second line metastatic Colorectal Cancer*	Taiho Pharmaceutical Co.	World except for North America and Asia
*In combination with oxaliplatin and nivolumab or bevacizumab Additional Information
*In combination with oxaliplatin and nivolumab or bevacizumab Additional Information

Lonsurf^® (trifluridine/tipiracil)	mCRC First Line	Taiho Pharmaceutical Co.	World except for North America and Asia	Phase 3
PRIMARY INDICATION First line metastatic Colorectal Cancer*		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for North America and Asia
PRIMARY INDICATION First line metastatic Colorectal Cancer* PARTNER Taiho Pharmaceutical Co. TERRITORY World except for North America and Asia
	First line metastatic Colorectal Cancer*	Taiho Pharmaceutical Co.	World except for North America and Asia
*In combination with bevacizumab
*In combination with bevacizumab

Lonsurf^® (trifluridine/tipiracil)	mGC Third Line		World except for North America and Asia	Registered
PRIMARY INDICATION Third line metastatic Gastric Cancer		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for North America and Asia
PRIMARY INDICATION Third line metastatic Gastric Cancer PARTNER Taiho Pharmaceutical Co. TERRITORY World except for North America and Asia
	Third line metastatic Gastric Cancer	Taiho Pharmaceutical Co.	World except for North America and Asia
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. Additional Information
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. Additional Information

Onivyde^® (Pegylated liposomal irinotecan)	mPAC post-gemcitabine	Ipsen	World except for the United States and Taiwan	Registered
PRIMARY INDICATION Metastatic Pancreatic Adenocarcinoma*		PARTNER Ipsen		PARTNER World except for the United States and Taiwan
PRIMARY INDICATION Metastatic Pancreatic Adenocarcinoma* PARTNER Ipsen TERRITORY World except for the United States and Taiwan
	Metastatic Pancreatic Adenocarcinoma*	Ipsen	World except for the United States and Taiwan
ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. *In combination with 5-FU/leucovorin Additional Information
ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. *In combination with 5-FU/leucovorin Additional Information

Anti-PD-1	Solid Tumors	Symphogen...	World	Phase 1
PRIMARY INDICATION Solid Tumors: Programmed Cell Death Protein 1*		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **		PARTNER World
PRIMARY INDICATION Solid Tumors: Programmed Cell Death Protein 1* PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. ** TERRITORY World
	Solid Tumors: Programmed Cell Death Protein 1*	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **	World
Monotherapy and in combination with Anti-LAG-3 or Anti-TIM-3 *License option not yet exercised
Monotherapy and in combination with Anti-LAG-3 or Anti-TIM-3 *License option not yet exercised

Anti-LAG-3	Solid Tumors	Symphogen...	World	Phase 1
PRIMARY INDICATION Solid Tumors- Lymphocyte-Activation Gene 3		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *		PARTNER World
PRIMARY INDICATION Solid Tumors- Lymphocyte-Activation Gene 3 PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. * TERRITORY World
	Solid Tumors- Lymphocyte-Activation Gene 3	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *	World
*License option not yet exercised
*License option not yet exercised

Anti-TIM-3	Solid Tumors	Symphogen...	World	Phase 1
PRIMARY INDICATION Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *		PARTNER World
PRIMARY INDICATION Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3 PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. * TERRITORY World
	Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *	World
*License option not yet exercised
*License option not yet exercised

Oncology Pipeline

Research & Development

Our Pipeline

Hematological Malignancies

ONCASPAR®

(pegaspargase)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

ASPARLAS™

(calaspargase pegol-mknl)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

PIXURVI®

(pixantrone)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

Anti-TIM-3

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

MCL1 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL-2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL- 2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL-2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL-2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL-2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

Anti-CD19

PRIMARY INDICATION

PARTNER

ONCASPAR^®

ASPARLAS^™

PIXURVI^®

Lonsurf^®